Comparative Pharmacology
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus TRIPLE SULFA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM SULFACETAMIDE versus TRIPLE SULFA.
SODIUM SULFACETAMIDE vs TRIPLE SULFA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, thereby blocking the synthesis of folic acid and ultimately nucleic acid synthesis, leading to bacteriostatic activity.
Inhibits bacterial dihydropteroate synthase (DHPS) and dihydrofolate reductase (DHFR), blocking folate synthesis essential for nucleic acid production.
1-2 drops of 10% or 30% solution into conjunctival sac every 2-3 hours during waking hours for 7-10 days.
1 g orally every 12 hours for 10 days (as sulfadiazine, sulfamethazine, and sulfamerazine combination).
None Documented
None Documented
7-12 hours in normal renal function; prolonged to 20-50 hours in renal impairment.
6-12 hours (sulfadiazine 10-13h, sulfamerazine 16-24h, sulfamethazine 7-12h); prolonged in renal impairment.
Renal: 85-100% unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
80-90% renal (glomerular filtration and tubular secretion) as unchanged drug and acetylated metabolites; 5-10% biliary/fecal.
Category A/B
Category C
Sulfonamide Antibiotic
Sulfonamide Antibiotic